The role of JAK/STAT signaling pathway and its inhibitors in diseases.

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · see citing works

Epidemiology of Parkinson's disease

de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · see citing works

STATs and Gene Regulation

Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979 · see citing works

Rheumatoid arthritis

Scott, D. L., Wolfe, F., & Huizinga, T. W. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,019 · see citing works

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772 · see citing works

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

Lotze, M. T., & Tracey, K. J. (2005) · Nature reviews. Immunology · doi:10.1038/nri1594 · Cited by 2,490 · see citing works

A quantitative analysis of kinase inhibitor selectivity

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · see citing works

Epidemiology of Parkinson’s disease

Tysnes, O., & Storstein, A. M. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1686-y · Cited by 2,437 · see citing works

The STATs of cancer — new molecular targets come of age

Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · see citing works

A family of cytokine-inducible inhibitors of signalling

Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066 · see citing works

Protein Tyrosine Phosphatases in the Human Genome

Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886 · see citing works

Intestinal homeostasis and its breakdown in inflammatory bowel disease

Maloy, K. J., & Powrie, F. M. (2011) · Nature · doi:10.1038/nature10208 · Cited by 1,876 · see citing works

SOCS proteins, cytokine signalling and immune regulation

Yoshimura, A., Naka, T., & Kubo, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2093 · Cited by 1,580 · see citing works

The JAK-STAT Pathway at Twenty

Stark, G. R., & Darnell, J. E., Jr. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,523 · see citing works

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

O'Shea, J., Schwartz, D., Villarino, A. V., Gadina, M., Mcinnes, I., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,472 · see citing works

A new protein containing an SH2 domain that inhibits JAK kinases

Endo, T. A., Masuhara, M., Yokouchi, M., Suzuki, R., Sakamoto, H., Mitsui, K., Matsumoto, A., Tanimura, S., Ohtsubo, M., Misawa, H., et al. (1997) · Nature · doi:10.1038/43213 · Cited by 1,408 · see citing works

Regulation of JAK–STAT signalling in the immune system

Shuai, K., & Liu, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1226 · Cited by 1,379 · see citing works

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

O’Shea, J. J., & Plenge, R. M. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,146 · see citing works

Role of P-Glycoprotein in Pharmacokinetics

Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 1,002 · see citing works

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Taylor, P. C., Keystone, E. C., van der Heijde, D. M. F. M., Weinblatt, M. E., Morales, L., Gonzaga, J. R., Yаkushin, S. S., Ishii, T., Emoto, K., Beattie, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608345 · Cited by 951 · see citing works

JAKs and STATs in immunity, immunodeficiency, and cancer

O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927 · see citing works

Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15

Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 888 · see citing works

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886 · see citing works

IL-6 in autoimmune disease and chronic inflammatory proliferative disease

Ishihara, K., & Hirano, T. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00027-8 · Cited by 807 · see citing works

The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells

Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G. R., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 774 · see citing works

Sepsis definitions: time for change

Vincent, J., Opal, S. M., Marshall, J. C., & Tracey, K. J. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61815-7 · Cited by 743 · see citing works

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

Ghoreschi, K., Jesson, M. I., Xiong, L., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 642 · see citing works

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Genovese, M. C., Kremer, J. M., Zamani, O., Ludivico, C. L., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 632 · see citing works

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

Clark, J. D., Flanagan, M. E., & Telliez, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 615 · see citing works

Mechanisms of Jak/STAT Signaling in Immunity and Disease

Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 554 · see citing works

Estrogen Regulation of Growth Hormone Action

Leung, K., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 544 · see citing works

VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligasesPreprint

Kamura, T., Maenaka, K., Kotoshiba, S., Matsumoto, M., Kohda, D., Conaway, R. C., Conaway, J. W., & Nakayama, K. I. (2004) · Genes & Development · doi:10.1101/gad.1252404 · Cited by 476 · see citing works

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

Fridman, J. S., Scherle, P., Collins, R. J., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B. A., Collier, P., Favata, M. F., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902819 · Cited by 472 · see citing works

Epidemiology of Parkinson's disease

Elbaz, A., Carcaillon‐Bentata, L., Kab, S., & Moisan, F. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 450 · see citing works

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

Fleischmann, R., Schiff, M. H., van der Heijde, D. M. F. M., Ramos-Remus, C., Spindler, A. J., Stanislav, M., Zerbini, C. A. F., Gurbuz, S., Dickson, C. L., de Bono, S., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39953 · Cited by 429 · see citing works

PIAS Proteins Modulate Transcription Factors by Functioning as SUMO-1 Ligases

Kotaja, N., Karvonen, U., Jänne, O. A., & Palvimo, J. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5222-5234.2002 · Cited by 426 · see citing works

MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration

Harms, A. S., Cao, S., Rowse, A. L., Thome, A. D., Li, X., Mangieri, L. R., Cron, R. Q., Shacka, J. J., Raman, C., & Standaert, D. G. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5610-12.2013 · Cited by 406 · see citing works

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Dougados, M., van der Heijde, D. M. F. M., Chen, Y., Greenwald, M., Drescher, E., Liu, J., Beattie, S. D., Witt, S., de la Torre, I., Gaich, C. L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210094 · Cited by 405 · see citing works

Cytokine‐inducible SH2 protein‐3 (CIS3/SOCS3) inhibits <i>Janus</i> tyrosine kinase by binding through the N‐terminal kinase inhibitory region as well as SH2 domain

Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A., & Yoshimura, A. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00263.x · Cited by 398 · see citing works

The myocardial JAK/STAT pathway: from protection to failure.

Boengler, K., Hilfiker-Kleiner, D., Drexler, H., Heusch, G., & Schulz, R. (2008) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2008.08.002 · Cited by 379 · see citing works

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases

Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 377 · see citing works

Interleukin-6 as a key player in systemic inflammation and joint destruction

Fonseca, J. E., Santos, M. J., Canhão, H. M., & Choy, E. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.01.012 · Cited by 374 · see citing works

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

Hodge, J. A., Kawabata, T. T., Krishnaswami, S., Clark, J. D., Telliez, J., Dowty, M. E., Menon, S. S., Lamba, M., & Zwillich, S. H. (2016) · PubMed · Cited by 374 · see citing works

Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediator

Harris, H. E., & Andersson, U. (2004) · European Journal of Immunology · doi:10.1002/eji.200424916 · Cited by 372 · see citing works

The IL-6/sIL-6R complex as a novel target for therapeutic approaches

Rose‐John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 362 · see citing works

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

Papp, K. A., Menter, A., Abe, M., Elewski, B. E., Feldman, S. R., Gottlieb, A. B., Langley, R. G. B., Luger, T. A., Thaçi, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 326 · see citing works

Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases

Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318 · see citing works

A new modality for immunosuppression: targeting the JAK/STAT pathway

O’Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 305 · see citing works

The role of the JAK/STAT signal pathway in rheumatoid arthritis

Malemud, C. J. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18776224 · Cited by 303 · see citing works

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

Boyle, D. L., Soma, K., Hodge, J., Kavanaugh, A., Mandel, D. R., Mease, P. J., Shurmur, R., Singhal, A. K., Wei, N., Rosengren, S., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206028 · Cited by 302 · see citing works

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

Dowty, M. E., Lin, J., Ryder, T. F., Wang, W., Walker, G. S., Vaz, A. D. N., Chan, G. L., Krishnaswami, S., & Prakash, C. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054940 · Cited by 279 · see citing works

Sepsis 2018: Definitions and Guideline Changes

Napolitano, L. M. (2018) · Surgical Infections · doi:10.1089/sur.2017.278 · Cited by 278 · see citing works

Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration

Qin, H., Buckley, J. A., Li, X., Liu, Y., Fox, T. H., Meares, G. P., Yu, H., Yan, Z., Harms, A. S., Li, Y., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4658-15.2016 · Cited by 275 · see citing works

Cardiovascular disease in autoimmune rheumatic diseases

Hollan, I., Meroni, P. L., Ahearn, J. M., Tervaert, J. W. C., Curran, S., Goodyear, C. S., Hestad, K. A., Kahaleh, B., Riggio, M. P., Shields, K. J., et al. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.03.013 · Cited by 273 · see citing works

Cytokines, STATs and liver disease.

Gao, B. (2005) · PubMed · Cited by 271 · see citing works

Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the Global Burden of Disease 2010 Study and the next steps forward

Hoy, D. G., Smith, E. U. R., Cross, M., Sànchez-Riera, L., Blyth, F., Buchbinder, R., Woolf, A. D., Driscoll, T., Brooks, P., & MARCH, L. M. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205393 · Cited by 270 · see citing works

Oclacitinib ( APOQUEL ® ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., Mann, D. W., & Mitton‐Fry, M. J. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12101 · Cited by 265 · see citing works

Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis.

Rudan, I., Sidhu, S., Papana, A., Meng, S., Xinwei, Y., Wang, W., Campbell–Page, R. M., Demaio, S., Nair, H., Sridhar, D., et al. (2015) · Europe PMC (PubMed Central) · doi:10.7189/jogh.05.010409 · Cited by 237 · see citing works

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Rompaey, L. V., Galien, R., van der Aar, E. M., Clément-Lacroix, P., Nelles, L., Smets, B., Lepescheux, L., Christophe, T., Conrath, K., Vandeghinste, N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201348 · Cited by 235 · see citing works

Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

Yuan, J., Zhang, F., & Niu, R.-F. (2015) · Scientific Reports · doi:10.1038/srep17663 · Cited by 235 · see citing works

Role of the JAK–STAT Pathway in Protection Against Myocardial Ischemia/Reperfusion Injury

Bolli, R., Dawn, B., & Xuan, Y. (2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00230-x · Cited by 234 · see citing works

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

Pardanani, A. D., Laborde, R. R., Lasho, T. L., Finke, C. M., Begna, K. H., Al‐Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A. A., Kowalski, M. M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 234 · see citing works

Regulation of cytokine signaling pathways by PIAS proteins

Shuai, K. (2006) · Cell Research · doi:10.1038/sj.cr.7310027 · Cited by 221 · see citing works

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Genovese, M. C., Smolen, J. S., Weinblatt, M. E., Burmester, G. R., Meerwein, S., Camp, H. S., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39808 · Cited by 204 · see citing works

Signaling pathways involved in MDSC regulation

Trikha, P., & Carson, W. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.003 · Cited by 201 · see citing works

SAF-Box, a Conserved Protein Domain That Specifically Recognizes Scaffold Attachment Region DNA

Kipp, M., Göhring, F., Ostendorp, T., van Drunen, C. M., DRIEL, R. V., Przybylski, M., & Fackelmayer, F. O. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7480-7489.2000 · Cited by 194 · see citing works

JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer

Slattery, M. L., Lundgreen, A., Kadlubar, S. A., Bondurant, K. L., & Wolff, R. K. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21841 · Cited by 192 · see citing works

Baricitinib: First Global Approval

Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0723-3 · Cited by 187 · see citing works

SOCS proteins in development and disease.

Trengove, M. C., & Ward, A. C. (2013) · Europe PMC (PubMed Central) · Cited by 185 · see citing works

The innate immune system in demyelinating disease

Mayo, L., Quintana, F. J., & Weiner, H. L. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01135.x · Cited by 184 · see citing works

A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy

Kremer, J. M., Emery, P., Camp, H. S., Friedman, A., Wang, L., Othman, A. A., Khan, N., Pangan, A. L., Jungerwirth, S., & Keystone, E. C. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39801 · Cited by 183 · see citing works

The many faces of the SOCS box

Piessevaux, J., Lavens, D., Peelman, F., & Tavernier, J. H. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.006 · Cited by 176 · see citing works

Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

Lopez-Diego, R., & Weiner, H. (2008) · Nature reviews. Drug discovery · doi:10.1038/nrd2358 · Cited by 173 · see citing works

Negative regulation of cytokine signaling and immune responses by SOCS proteins.

Yoshimura, A., Nishinakamura, H., Matsumura, Y., & Hanada, T. (2005) · Arthritis Research · doi:10.1186/ar1741 · Cited by 162 · see citing works

PIAS proteins promote SUMO-1 conjugation to STAT1

Ungureanu, D., Vanhatupa, S., Kotaja, N., Yang, J., Aittomäki, S., Jänne, O. A., Palvimo, J. J., & Silvennoinen, O. (2003) · Blood · doi:10.1182/blood-2002-12-3816 · Cited by 159 · see citing works

Astaxanthin Inhibits JAK/STAT-3 Signaling to Abrogate Cell Proliferation, Invasion and Angiogenesis in a Hamster Model of Oral Cancer

Kowshik, J., Baba, A. B., Giri, H., Reddy, G. D., Dixit, M., & Nagini, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109114 · Cited by 158 · see citing works

Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management

Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24592 · Cited by 158 · see citing works

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Papp, K. A., Krueger, J. G., Feldman, S. R., Langley, R. G. B., Thaçi, D., Torii, H., Tyring, S. K., Wolk, R. A., Gardner, A., Mebus, C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.013 · Cited by 157 · see citing works

Therapeutic Efficacy of Suppressing the JAK/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis

Liu, Y., Holdbrooks, A. T., Sarno, P. D., Rowse, A. L., Yanagisawa, L. L., McFarland, B. C., Harrington, L. E., Raman, C., Sabbaj, S., Benveniste, E. N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301513 · Cited by 155 · see citing works

Signaling by STATs.

Ivashkiv, L. B., & Hu, X. (2004) · Arthritis Research · doi:10.1186/ar1197 · Cited by 152 · see citing works

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 151 · see citing works

SOCS-6 Binds to Insulin Receptor Substrate 4, and Mice Lacking the SOCS-6 Gene Exhibit Mild Growth Retardation

Krebs, D. L., Uren, R. T., Metcalf, D., Rakar, S., Zhang, J., Starr, R., Souza, D. P. D., Hanzinikolas, K., Eyles, J. L., Connolly, L., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4567-4578.2002 · Cited by 150 · see citing works

Established and novel disease‐modifying treatments in multiple sclerosis

Cross, A. H., & Naismith, R. T. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12203 · Cited by 142 · see citing works

Interleukin‐31: its role in canine pruritus and naturally occurring canine atopic dermatitis

Gonzales, A. J., Humphrey, W. R., Messamore, J. E., Fleck, T. J., Fici, G. J., Shelly, J. A., Teel, J. F., Bammert, G. F., Dunham, S. A., Fuller, T. E., et al. (2013) · Veterinary Dermatology · doi:10.1111/j.1365-3164.2012.01098.x · Cited by 139 · see citing works

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production

LaBranche, T. P., Jesson, M. I., Radi, Z. A., Storer, C. E., Guzova, J. A., Bonar, S. L., Thompson, J., Happa, F. A., Stewart, Z. S., Zhan, Y., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34649 · Cited by 139 · see citing works

The Specific Roles of JAK/STAT Signaling Pathway in Sepsis

Cai, B., Cai, J., Luo, Y., Chen, C., & Zhang, S. (2015) · Inflammation · doi:10.1007/s10753-015-0135-z · Cited by 138 · see citing works

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Namour, F., Diderichsen, P. M., Cox, E. H., Vayssière, B., der Aa, A. V., Tasset, C. T., & Klooster, G. A. E. V. '. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0240-z · Cited by 138 · see citing works

Chemical and Mechanistic Approaches to the Study of Protein Tyrosine Phosphatases

Zhang, Z.-Y. (2003) · Accounts of Chemical Research · doi:10.1021/ar020122r · Cited by 138 · see citing works

The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease

Schapansky, J., Nardozzi, J. D., & LaVoie, M. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.049 · Cited by 132 · see citing works

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Singer, J. W., Al‐Fayoumi, S., Ma, H., Komrokji, R. S., Mesa, R. A., & Verstovšek, S. (2016) · Journal of Experimental Pharmacology · doi:10.2147/jep.s110702 · Cited by 129 · see citing works

Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases

Yu, Z.-H., & Zhang, Z. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00105 · Cited by 128 · see citing works

Structure of the SOCS4-ElonginB/C Complex Reveals a Distinct SOCS Box Interface and the Molecular Basis for SOCS-Dependent EGFR Degradation

Bullock, A. N., Rodríguez, M. C., Debreczeni, J. E., Songyang, Z., & Knapp, S. (2007) · Structure · doi:10.1016/j.str.2007.09.016 · Cited by 127 · see citing works

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis

English, C., & Aloi, J. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.03.001 · Cited by 126 · see citing works

Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

Zhou, T., Georgeon, S., Moser, R., Moore, D. J., Caflisch, A., & Hantschel, O. D. (2013) · Leukemia · doi:10.1038/leu.2013.205 · Cited by 125 · see citing works

STATs: An Old Story, Yet Mesmerizing

Saeid, A., Saki, N., Ahmadvand, M., Asghari, F., Salari, F., & Rahim, F. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 124 · see citing works

Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation

Nunes, C., Almeida, L. M., Barbosa, R. M., & Laranjinha, J. A. N. (2016) · Food & Function · doi:10.1039/c6fo01529h · Cited by 123 · see citing works

Swertiamarin attenuates inflammation mediators via modulating NF-κB/I κB and JAK2/STAT3 transcription factors in adjuvant induced arthritis

Saravanan, S., Islam, V. I. H., Narasimhan, P. B., Pandikumar, P., Thirugnanasambantham, K., Chellappandian, M., Raj, C. S. D., Paulraj, M. G., & Savarimuthu Ignacimuthu, S. J. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.005 · Cited by 121 · see citing works

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

Papp, K. A., Pariser, D. M., Catlin, M., Wierz, G., Ball, G., Akinlade, B., Zeiher, B. G., & Krueger, J. G. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13745 · Cited by 117 · see citing works

Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis

Mohamed, M. F., Camp, H. S., Jiang, P. X., Padley, R. J., Asatryan, A., & Othman, A. A. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0419-y · Cited by 117 · see citing works

Therapeutic targets for rheumatoid arthritis: Progress and promises

Alghasham, A., & Rasheed, Z. (2014) · Autoimmunity · doi:10.3109/08916934.2013.873413 · Cited by 116 · see citing works

The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels

Isomäki, P., Junttila, I., Vidqvist, K.-L., Korpela, M. M., & Silvennoinen, O. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu430 · Cited by 116 · see citing works

Involvement of the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway in Multiple Sclerosis and the Animal Model of Experimental Autoimmune Encephalomyelitis

Benveniste, E. N., Liu, Y., McFarland, B. C., & Qin, H. (2014) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0012 · Cited by 114 · see citing works

Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy

Chikuma, S., Kanamori, M., Mise‐Omata, S., & Yoshimura, A. (2017) · Cancer Science · doi:10.1111/cas.13194 · Cited by 112 · see citing works

Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson's disease

Chen, Y., Qi, B.-Q., Xu, W., MA, B., Li, L., Chen, Q., Qian, W., Liu, X., & Qu, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4136 · Cited by 109 · see citing works

Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases

Malemud, C. J., & Pearlman, E. M. (2009) · Current Signal Transduction Therapy · doi:10.2174/157436209789057467 · Cited by 103 · see citing works

Does ruxolitinib prolong the survival of patients with myelofibrosis?

Cervantes, F., & Pereira, A. (2016) · Blood · doi:10.1182/blood-2016-11-731604 · Cited by 99 · see citing works

A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model

Ito, M., Yamazaki, S., Yamagami, K., Kuno, M., Morita, Y., Okuma, K., Nakamura, K., Chida, N., Inami, M., Inoue, T., et al. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.12.001 · Cited by 96 · see citing works

Proinflammatory Cytokine IL‐6 and JAK‐STAT Signaling Pathway in Myeloproliferative Neoplasms

Čokić, V. P., Ajtić, O. M., Beleslin‐Čokić, B. B., Marković, D. C., Kovačić, M. V., Diklić, M., Kraguljac‐Kurtović, N., Damjanovic, S. S., Milenković, P., Gotić, M., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/453020 · Cited by 92 · see citing works

SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Mahony, R., Ahmed, S., Diskin, C., & Stevenson, N. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2234-x · Cited by 92 · see citing works

Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer

Zundler, S., & Neurath, M. F. (2016) · Vaccines · doi:10.3390/vaccines4010005 · Cited by 91 · see citing works

Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling

Macha, M. A., Rachagani, S., Gupta, S., Pai, P., Ponnusamy, M. P., Batra, S. K., & Jain, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.037 · Cited by 87 · see citing works

JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases

Gao, Q., Liang, X., Shaikh, A. S., Zang, J., Xu, W., & Zhang, Y. (2017) · Current Drug Targets · doi:10.2174/1389450117666161207163054 · Cited by 84 · see citing works

Do Th17 Lymphocytes and IL-17 Contribute to Parkinson's Disease? A Systematic Review of Available Evidence

Storelli, E., Cassina, N., Rasini, E., Marino, F., & Cosentino, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00013 · Cited by 84 · see citing works

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials

Klünder, B., Mohamed, M.-E. F., & Othman, A. A. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0605-6 · Cited by 83 · see citing works

The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease

Holleran, G. E., Lopetuso, L. R., Petito, V., Graziani, C., Ianiro, G., McNamara, D. A., Gasbarrini, A., & Scaldaferri, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102020 · Cited by 82 · see citing works

Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis

Ramamoorthi, G., & Rasool, M. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.09.003 · Cited by 76 · see citing works

Melittin enhances apoptosis through suppression of IL-6/sIL-6R complex-induced NF-κB and STAT3 activation and Bcl-2 expression for human fibroblast-like synoviocytes in rheumatoid arthritis

Kim, S., Park, K.-Y., Yoon, W.-C., Park, S., Park, K., Yoo, D., & Choe, J. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.01.004 · Cited by 75 · see citing works

Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines

Sağlam, A. S. Y., Alp, E., Elmazoğlu, Z., & Menevşe, S. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327115595686 · Cited by 74 · see citing works

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

Nakayamada, S., Kubo, S., Iwata, S., & Tanaka, Y. (2016) · BioDrugs · doi:10.1007/s40259-016-0190-5 · Cited by 74 · see citing works

Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors

Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.004 · Cited by 74 · see citing works

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

Pérez, C., González‐Rincón, J., Onaindía, A., Almaráz, C., García‐Díaz, N., Pisonero, H., Curiel‐Olmo, S., Gómez, S., Cereceda, L., Madureira, R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.132837 · Cited by 73 · see citing works

Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials

D’Amico, F., Fiorino, G., Furfaro, F., Allocca, M., & Danese, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1492547 · Cited by 72 · see citing works

Brief Report: T Cell Expression of Granulocyte–Macrophage Colony‐Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity

Piper, C. J. M., Pesenacker, A. M., Bending, D., Thirugnanabalan, B., Varsani, H., Wedderburn, L. R., & Nistala, K. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38647 · Cited by 68 · see citing works

IL‐31‐induced pruritus in dogs: a novel experimental model to evaluate anti‐pruritic effects of canine therapeutics

Gonzales, A. J., Fleck, T. J., Humphrey, W. R., Galvan, B. A., Aleo, M. M., Mahabir, S. P., Tena, J., Greenwood, K. G., & McCall, R. B. (2015) · Veterinary Dermatology · doi:10.1111/vde.12280 · Cited by 66 · see citing works

17β-Oestradiol enhances the expansion and activation of myeloid-derived suppressor cells via signal transducer and activator of transcription (STAT)−3 signalling in human pregnancy

Pan, T. S., Li, Z., Wu, S., Cao, Y., Yang, Q., Cai, Z., Cai, X., Zhao, W., Ma, N., Zhang, W., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12790 · Cited by 66 · see citing works

Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation

Boyle, K., Zhang, J., Nicholson, S. E., Trounson, E., Babon, J. J., McManus, E. J., Nicola, N. A., & Robb, L. G. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.11.002 · Cited by 65 · see citing works

Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?

Speirs, C., Williams, J. J. L., Riches‐Suman, K., Salt, I. P., & Palmer, T. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.001 · Cited by 61 · see citing works

Understanding the role of SOCS signaling in neurodegenerative diseases: Current and emerging concepts

Cianciulli, A., Calvello, R., Porro, C., Trotta, T., & Panaro, M. A. (2017) · Cytokine &amp; Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.07.005 · Cited by 59 · see citing works

Momelotinib therapy for myelofibrosis: a 7-year follow-up

Tefferi, A., Barraco, D., Lasho, T. L., Shah, S. H., Begna, K. H., Al‐Kali, A., Hogan, W. J., Litzow, M. R., Hanson, C. A., Ketterling, R. P., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0067-6 · Cited by 59 · see citing works

Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis

Li, H., Zhao, W., Shi, Y. P., Li, Y., Zhang, L., Zhang, H., & Wang, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-3534-8 · Cited by 55 · see citing works

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

Namour, F., Desrivot, J., der Aa, A. V., Harrison, P., Tasset, C. T., & Klooster, G. A. E. V. '. (2016) · Drug Metabolism Letters · doi:10.2174/1872312810666151223103353 · Cited by 55 · see citing works

Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection

O'Brien, V. P., Hannan, T. J., Schaeffer, A. J., & Hultgren, S. J. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000130 · Cited by 50 · see citing works

The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation

Ardoin, S. P., & Pisetsky, D. S. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0054-z · Cited by 49 · see citing works

Matrine induces the apoptosis of fibroblast-like synoviocytes derived from rats with collagen-induced arthritis by suppressing the activation of the JAK/STAT signaling pathway

Yang, Y., Dong, Q., & Li, R. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2843 · Cited by 49 · see citing works

SOCS-1 Localizes to the Microtubule Organizing Complex-Associated 20S Proteasome

Vuong, B. Q., Arenzana, T. L., Showalter, B. M., Losman, J. A., Chen, X. P., Mostecki, J. W., Banks, A. S., Limnander, A., Fernandez, N., & Rothman, P. B. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.9092-9101.2004 · Cited by 48 · see citing works

Are Janus kinase inhibitors superior over classic biologic agents in RA patients?

Kotyla, P. J. (2018) · BioMed Research International · doi:10.1155/2018/7492904 · Cited by 47 · see citing works

Growth hormone signalling: sprouting links between pathways, human genetics and therapeutic options

Pilecka, I., Whatmore, A. J., van Huijsduijnen, R. H., Destenaves, B., & Clayton, P. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.11.004 · Cited by 46 · see citing works

Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells

McCandless, E. E., Rugg, C. A., Fici, G. J., Messamore, J. E., Aleo, M. M., & Gonzales, A. J. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.10.017 · Cited by 45 · see citing works

Novel Immunotherapeutic Avenues for Rheumatoid Arthritis

Semerano, L., Minichiello, É., Bessis, N., & Boissier, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.005 · Cited by 45 · see citing works

Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis

Iwata, S., & Tanaka, Y. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1189826 · Cited by 45 · see citing works

The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma

Huang, Y., Zhang, Y., Ge, L., Lin, Y., & Kwok, H. F. (2018) · Cancers · doi:10.3390/cancers10030082 · Cited by 45 · see citing works

Increased Levels of Pro-Inflammatory and Anti-Inflammatory Cellular Responses in Parkinson’s Disease Patients: Search for a Disease Indicator

Yang, L., Guo, C., Zhu, J., Feng, Y., Chen, W.-L., Feng, Z.-Z., Wang, D., Sun, S., Lin, W., & Wang, Y. (2017) · Medical Science Monitor · doi:10.12659/msm.904240 · Cited by 43 · see citing works

Inhibition of Janus Kinase 2 and Signal Transduction and Activator of Transcription 3 Protect Against Cecal Ligation and Puncture-Induced Multiple Organ Damage and Mortality

Hui, L., Yao, Y., Wang, S., Yu, Y., Dong, N., Li, H., & Sheng, Z. (2009) · Journal of Trauma: Injury, Infection &amp; Critical Care · doi:10.1097/ta.0b013e318164d05f · Cited by 42 · see citing works

The Functions and Therapeutic Potential of Heat Shock Proteins in Inflammatory Bowel Disease—An Update

Hoter, A., & Naim, H. Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215331 · Cited by 42 · see citing works

STAT3 Dysregulation in Mature T and NK Cell Lymphomas

Seffens, A., Herrera, A. M., Tegla, C., Buus, T. B., Hymes, K. B., Ødum, N., Geskin, L. J., & Koralov, S. B. (2019) · Cancers · doi:10.3390/cancers11111711 · Cited by 42 · see citing works

Filgotinib for the treatment of rheumatoid arthritis

Taylor, P. C., Azeez, M., & Kiriakidis, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1372422 · Cited by 41 · see citing works

Editorial: Decernotinib: A Next‐Generation Jakinib

Gadina, M., Schwartz, D. M., & O’Shea, J. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39463 · Cited by 40 · see citing works

Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases

Liu, Y., Gibson, S. A., Benveniste, E. N., & Qin, H. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2016015517 · Cited by 40 · see citing works

VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions

Zetterberg, C., Maltais, F., Laitinen, L., Liao, S., Tsao, H., Chakilam, A., & Hariparsad, N. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.071100 · Cited by 40 · see citing works

Cytokines in canine inflammatory bowel disease

Kołodziejska-Sawerska, A., Rychlik, A., Depta, A., Wdowiak, M., Nowicki, M., & Kander, M. (2013) · Polish Journal of Veterinary Sciences · doi:10.2478/pjvs-2013-0025 · Cited by 39 · see citing works

Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster

Yamaoka, K. (2016) · Drug Safety · doi:10.1007/s40264-016-0430-0 · Cited by 39 · see citing works

Baricitinib for the treatment of rheumatoid arthritis

Kubo, S., Nakayamada, S., & Tanaka, Y. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1214576 · Cited by 38 · see citing works

Efficacy of baricitinib in the treatment of rheumatoid arthritis

Richez, C., Truchetet, M., Kostine, M., Schaeverbeke, T., & Bannwarth, B. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359256 · Cited by 38 · see citing works

Tofacitinib: A New Oral Therapy for Psoriasis

Azevedo, A., & Torres, T. R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0596-y · Cited by 37 · see citing works

The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation

(2008) · doi:10.3109/s10165-008-0054-z · Cited by 35 · see citing works

Ruxolitinib

Yang, L. P. H., & Keating, G. M. (2012) · Drugs · doi:10.2165/11209340-000000000-00000 · Cited by 33 · see citing works

Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors

Jaime‐Figueroa, S., de Vicente, J., Hermann, J. C., Jahangir, A. M., Jin, S., Kuglstatter, A., Lynch, S. M., Menke, J. G., Niu, L., Patel, V. P., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.015 · Cited by 33 · see citing works

Introduction to JAK/STAT signaling and the vasculature

Marrero, M. B. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.09.002 · Cited by 33 · see citing works

Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment

Fernández-Ruiz, J. C., Ramos-Remus, C., Sánchez‐Corona, J., Castillo-Ortiz, J. D., Castaneda-Sanchez, J. J., Bastián, Y., Romo-García, M. F., Ochoa-González, F. D. L., Monsiváis-Urenda, A. E., González‐Amaro, R., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.028 · Cited by 32 · see citing works

Systems biology of JAK/STAT signalling

Pfeifer, A. C., Timmer, J., & Klingmüller, U. (2008) · Essays in Biochemistry · doi:10.1042/bse0450109 · Cited by 31 · see citing works

STAT5a and STAT6 gene expression levels in multiple sclerosis patients

Hatami, M., Salmani, T., Arsang‐Jang, S., Omrani, M. D., Mazdeh, M., Ghafouri‐Fard, S., Sayad, A., & Taheri, M. (2017) · Cytokine · doi:10.1016/j.cyto.2017.10.022 · Cited by 31 · see citing works

The Effect of Verapamil, a P‐Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once‐Daily JAK Inhibitor

Zhu, T., Howieson, C., Wojtkowski, T., Garg, J. P., Han, D., Fisniku, O., & Keirns, J. J. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.344 · Cited by 29 · see citing works

Ocrelizumab for the treatment of multiple sclerosis

Bigaut, K., Seze, J. D., & Collongues, N. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1561284 · Cited by 29 · see citing works

Chemical JAK inhibitors for the treatment of rheumatoid arthritis

Nakayamada, S., Kubo, S., Iwata, S., & Tanaka, Y. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241237 · Cited by 28 · see citing works

National Institute for Health and Clinical Excellence

(2010) · Journal of Neonatal Nursing · doi:10.1016/j.jnn.2010.11.006 · Cited by 26 · see citing works

Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

Sapre, M., Tremblay, D. A., Wilck, E. J., James, A., Leiter, A., Coltoff, A. R., Koshy, A. G., Kremyanskaya, M., Hoffman, R., Mascarenhas, J. O., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53056-x · Cited by 25 · see citing works

N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells

Dagvadorj, A., Tan, S., Liao, Z., Xie, J., Nurmi, M. J., Alanen, K. A., Rui, H., Mirtti, T. K., & Nevalainen, M. T. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.09.008 · Cited by 24 · see citing works

Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-γ through JAK/STAT pathway by translational regulation

Tamai, M., Kawakami, A., Tanaka, F., Miyashita, T., Nakamura, H., Iwanaga, N., Izumi, Y., Arima, K., Aratake, K., Huang, M., et al. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.12.001 · Cited by 22 · see citing works

Endothelin-1 stimulates expression of cyclin D1 and S-phase kinase–associated protein 2 by activating the transcription factor STAT3 in cultured rat astrocytes

Kōyama, Y., Sumie, S., Nakano, Y., Nagao, T., Tokumaru, S., & Michinaga, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005614 · Cited by 22 · see citing works

Pharmacodynamic Analysis of Tofacitinib and Basiliximab in Kidney Allograft Recipients

Vafadari, R., Quaedackers, M. E., Kho, M. M. L., Mol, W. M., Chan, G. L., Weimar, W., & Baan, C. C. (2012) · Transplantation · doi:10.1097/tp.0b013e3182626b5a · Cited by 17 · see citing works

Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients

Nazdik, M. K., Taheri, M. N., Sajjadi, E., Arsang‐Jang, S., Koohpar, Z. K., Inoko, H., & Sayad, A. (2016) · Human Antibodies · doi:10.3233/hab-160296 · Cited by 16 · see citing works

GYF-21, an Epoxide 2-(2-Phenethyl)-Chromone Derivative, Suppresses Innate and Adaptive Immunity via Inhibiting STAT1/3 and NF-κB Signaling Pathways

Guo, R., Zhao, Y.-F., Li, J., Gu, Y., Huo, H.-X., Li, S., Song, Y.-L., Zhu, Z.-X., & Tu, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00281 · Cited by 15 · see citing works

Calcineurin B in CD4+ T Cells Prevents Autoimmune Colitis by Negatively Regulating the JAK/STAT Pathway

Mencarelli, A., Vacca, M., Khameneh, H. J., Acerbi, E., Tay, A., Zolezzi, F., Poidinger, M., & Mortellaro, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00261 · Cited by 15 · see citing works

Multiple outcome meta-analysis of gene-expression data in inflammatory bowel disease

Vennou, K. E., Piovani, D., Kontou, P. I., Bonovas, S., & Bagos, P. G. (2019) · Genomics · doi:10.1016/j.ygeno.2019.09.019 · Cited by 15 · see citing works

Filgotinib in Crohn’s Disease: JAK Is Back

Danese, S., Fiorino, G., & Peyrin‐Biroulet, L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.040 · Cited by 14 · see citing works

Molecular components of JAK/STAT signaling pathway and its interaction with transcription machinery

Shaposhnikov, A. V., Комарьков, И. Ф., Lebedeva, L. A., & Shidlovskii, Y. V. (2013) · Molecular Biology · doi:10.1134/s0026893313030126 · Cited by 13 · see citing works

Intraarticular gene transfer of SPRY2 suppresses adjuvant-induced arthritis in rats

Zhang, W., Zhu, J., Du, Z., Yu, J., Xu, Y., & Wang, F. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6618-x · Cited by 11 · see citing works

A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence

Wade, R., Hodgson, R. M., Biswas, M., Harden, M., & Woolacott, N. F. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0447-3 · Cited by 11 · see citing works

Daclizumab-induced encephalitis in multiple sclerosis

Bianchi, A., & Ciccarelli, O. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519845079 · Cited by 10 · see citing works

Immune characteristics study of AG490, a signal pathway inhibitor, in EAE model mice

Zhao, Z., Mao, Z., Yin, J., Shu, Y., Qiu, W., Lu, Z., & Hu, X. (2016) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2016.08.015 · Cited by 7 · see citing works

Inhibitors of JAK for the treatment of rheumatoid arthritis: rationale and clinical data

Malemud, C. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.169 · Cited by 6 · see citing works

Ruxolitinib for the Treatment of Disease-Related Splenomegaly or Symptoms in Adult Patients with Myelofibrosis

Liew, E., & Lipton, J. H. (2014) · International Journal of Hematologic Oncology · doi:10.2217/ijh.14.35 · Cited by 1 · see citing works

The JAK/STAT signaling pathway: from bench to clinic

Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633 · see citing works

Microglia polarization from M1 to M2 in neurodegenerative diseases

Guo, S., Wang, H., & Yin, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.815347 · Cited by 920 · see citing works

Signaling pathways and targeted therapy for myocardial infarction

Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00925-z · Cited by 855 · see citing works

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 753 · see citing works

Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy

Liu, J., Han, X., Zhang, T., Tian, K., Li, Z., & Luo, F. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01512-7 · Cited by 718 · see citing works

Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets

Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 660 · see citing works

Macrophage Polarization and Its Role in Liver Disease

Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 583 · see citing works

The interaction between ferroptosis and inflammatory signaling pathways

Chen, Y., Fang, Z., Yi, X., Wei, X., & Jiang, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05716-0 · Cited by 589 · see citing works

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 520 · see citing works

Microglia Mediated Neuroinflammation in Parkinson’s Disease

Işık, S., Yeman-Kıyak, B., Akbayır, R., Şeyhali-Abutayeh, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 402 · see citing works

Therapeutic Effects of Green Tea Polyphenol (‒)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis

Mokrá, D., Jošková, M., & Mokrý, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010340 · Cited by 380 · see citing works

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1110765 · Cited by 351 · see citing works

The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review

Liao, H., Ye, J., Gao, L., & Liu, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110917 · Cited by 341 · see citing works

Nrf2-mediated anti-inflammatory polarization of macrophages as therapeutic targets for osteoarthritis

Wang, L., & He, C.-Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967193 · Cited by 352 · see citing works

The role of the immune microenvironment in bone, cartilage, and soft tissue regeneration: from mechanism to therapeutic opportunity

Xiong, Y., Mi, B., Lin, Z., Hu, Y., Yu, L., Zha, K., Panayi, A. C., Yu, T., Chen, L., Liu, Z.-P., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00426-8 · Cited by 295 · see citing works

Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials

Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293 · see citing works

Neutrophil diversity and function in health and disease

Zhang, F., Xia, Y., Su, J., Quan, F., Zhou, H., Li, Q., Feng, Q., Lin, C., Wang, D., & Jiang, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02049-y · Cited by 283 · see citing works

Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer

Alipour, M. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00518-5 · Cited by 247 · see citing works

Intestinal barrier damage, systemic inflammatory response syndrome, and acute lung injury: A troublesome trio for acute pancreatitis

Ge, P., Luo, Y., Okoye, C. S., Chen, H., Liu, J., Zhang, G., Xu, C., & Chen, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110770 · Cited by 247 · see citing works

JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions

Sarapultsev, A., Gusev, E., Komelkova, M. V., Utepova, I. A., Luo, S., & Hu, D. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00151-1 · Cited by 226 · see citing works

Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis

Liu, S., Ma, H., Zhang, H., Deng, C., & Xin, P. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108793 · Cited by 208 · see citing works

JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies

Rah, B., Rather, R. A., Bhat, G. R., Baba, A. B., Mushtaq, I., Farooq, M., Yousuf, T., Dar, S. B., Parveen, S., Hassan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.821344 · Cited by 202 · see citing works

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Chen, J., Liu, Q., He, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958790 · Cited by 164 · see citing works

Drug Resistance in Colorectal Cancer: From Mechanism to Clinic

Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160 · see citing works

Macrophage-specific inhibition of the histone demethylase JMJD3 decreases STING and pathologic inflammation in diabetic wound repair

Audu, C. O., Melvin, W. J., Joshi, A., Wolf, S., Moon, J. Y., Davis, F. M., Barrett, E. C., Mangum, K. D., Deng, H., Xing, X., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00919-5 · Cited by 159 · see citing works

Microglial activation states and their implications for Alzheimer's Disease

Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 155 · see citing works

Molecular mechanism of the anti-inflammatory effects of plant essential oils: A systematic review

Zhao, Q., Zhu, L.-Y., Wang, S., Gao, Y., & Jin, F. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115829 · Cited by 137 · see citing works

Pyrroloquinoline-Quinone Is More Than an Antioxidant: A Vitamin-like Accessory Factor Important in Health and Disease Prevention

Jonscher, K. R., Chowanadisai, W., & Rucker, R. B. (2021) · Biomolecules · doi:10.3390/biom11101441 · Cited by 128 · see citing works

Inflammatory response of nanoparticles: Mechanisms, consequences, and strategies for mitigation

Summer, M., Ashraf, R., Ali, S., Bach, H., Noor, S., Noor, Q., Riaz, S., & Khan, R. R. M. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2024.142826 · Cited by 119 · see citing works

Targeting inflammation as cancer therapy

Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 122 · see citing works

The role of Janus kinase signaling in the pathology of atopic dermatitis

Guttman‐Yassky, E., Irvine, A. D., Brunner, P. M., Kim, B., Boguniewicz, M., Parmentier, J. M., Platt, A. M., & Kabashima, K. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.010 · Cited by 118 · see citing works

Targeting STAT3 Signaling Pathway in Colorectal Cancer

Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2021) · Biomedicines · doi:10.3390/biomedicines9081016 · Cited by 113 · see citing works

Alpinetin inhibits neuroinflammation and neuronal apoptosis via targeting the JAK2/STAT3 signaling pathway in spinal cord injury

Xiao, S., Zhang, Y., Liu, Z., Li, A., Tong, W., Xiong, X., Nie, J., Zhong, N., Zhu, G., Liu, J., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14085 · Cited by 115 · see citing works

Impact of Peripheral Inflammation on Blood–Brain Barrier Dysfunction and Its Role in Neurodegenerative Diseases

Beltrán-Velasco, A. I., & Clemente‐Suárez, V. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062440 · Cited by 111 · see citing works

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS

Toader, C., Tătaru, C. P., Munteanu, O., Șerban, M., Covache-Busuioc, R.-A., Ciurea, A. V., & Enyedi, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312613 · Cited by 106 · see citing works

Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets

Jeon, S., Jeon, Y., Lim, J.-Y., Kim, Y., Cha, B., & Kim, W. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02070-1 · Cited by 97 · see citing works

Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment

Javed, Z., Sadia, H., Iqbal, M. J., Shamas, S., Malik, K. A., Ahmed, R., Raza, S., Butnariu, M., Martins, N. A., & Sharifi‐Rad, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01888-x · Cited by 100 · see citing works

From nature to therapy: Luteolin's potential as an immune system modulator in inflammatory disorders

Hussain, M. S., Gupta, G., Goyal, A., Thapa, R., Almalki, W. H., Kazmi, I., Alzarea, S. I., Fuloria, S., Meenakshi, D. U., Jakhmola, V., et al. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23482 · Cited by 98 · see citing works

Ferulic Acid: A Review of Pharmacology, Toxicology, and Therapeutic Effects on Pulmonary Diseases

Zhai, Y., Wang, T., Fu, Y., Yu, T., Ding, Y. P., & Nie, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098011 · Cited by 96 · see citing works

Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy

Zhuang, H., Liang, Z., Ma, G., Qureshi, A., Ran, X., Feng, C., Liu, X., Yan, X., & Shen, L. (2024) · MedComm · doi:10.1002/mco2.497 · Cited by 106 · see citing works

Punicalagin Regulates Signaling Pathways in Inflammation-Associated Chronic Diseases

Xu, J., Cao, K., Liu, X., Zhao, L., Feng, Z., & Liu, J. (2021) · Antioxidants · doi:10.3390/antiox11010029 · Cited by 91 · see citing works

Oxidative Stress in Intestinal Ischemia-Reperfusion

Li, G., Wang, S., & Fan, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.750731 · Cited by 89 · see citing works

The involvement of JAK/STAT signaling pathway in the treatment of Parkinson's disease

Lashgari, N., Roudsari, N. M., Momtaz, S., Sathyapalan, T., Abdolghaffari, A. H., & Sahebkar, A. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577758 · Cited by 90 · see citing works

The reciprocal interactions between microglia and T cells in Parkinson’s disease: a double-edged sword

Xu, Y., Li, Y., Wang, C., Han, T., Liu, H., Sun, L., Hong, J., Hashimoto, M., & Wei, J. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02723-y · Cited by 88 · see citing works

tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB

Xu, R., Du, A., Deng, X., Du, W., Zhang, K., Li, J., Lu, Y., Wei, X., Yang, Q., & Tang, H. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03132-6 · Cited by 88 · see citing works

Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer

Marković, I., & Savvides, S. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01557 · Cited by 86 · see citing works

The Dysregulation of Inflammatory Pathways Triggered by Copper Exposure

Deng, H., Zhu, S., Yang, H., Cui, H., Guo, H., Deng, J., Ren, Z., Geng, Y., Ouyang, P., Xu, Z., et al. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03171-0 · Cited by 86 · see citing works

Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway

Yin, Q., Wang, L., Yu, H., Chen, D., Zhu, W., & Sun, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.716672 · Cited by 86 · see citing works

Reactive gliosis in traumatic brain injury: a comprehensive review

Amlerova, Z., Chmelová, M., Anděrová, M., & Vargová, L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1335849 · Cited by 86 · see citing works

Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome

Baghdassarian, H., Blackstone, S. A., Clay, G. M., Philips, R. L., Matthíasardóttir, B., Nehrebecky, M. E., Hua, V. K., McVicar, R. N., Liu, Y., Tucker, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2202318 · Cited by 83 · see citing works

The potential roles of JAK/STAT signaling in the progression of osteoarthritis

Zhou, Q., Ren, Q., Jiao, L., Huang, J., Yi, J., Chen, J.-C., Lai, J., Ji, G.-L., & Zheng, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1069057 · Cited by 80 · see citing works

Pharmacological Properties of 4′, 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways

Abid, R., Ghazanfar, S., Farid, A., Sulaman, S. M., Idrees, M., Amen, R. A., Muzammal, M., Shahzad, M. K., Mohamed, M. O., Khaled, A. A., et al. (2022) · Molecules · doi:10.3390/molecules27134304 · Cited by 79 · see citing works

Microalgae-Derived Extracellular Vesicles Synergize with Herbal Hydrogel for Energy Homeostasis in Osteoarthritis Treatment

Feng, L., Zheng, Y., Zhao, C., Li, L., Hu, Y., Wang, C., Wang, R., Feng, T., Liu, X., Cui, J., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16085 · Cited by 78 · see citing works

Ferroptosis: an important player in the inflammatory response in diabetic nephropathy

Li, J., Li, L., Zhang, Z., Chen, P., Shu, H., Yang, C., Chu, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1294317 · Cited by 81 · see citing works

Pharmacological Effects of Centella asiatica on Skin Diseases: Evidence and Possible Mechanisms

Park, K. S. (2021) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2021/5462633 · Cited by 79 · see citing works

Microglial polarization in TBI: Signaling pathways and influencing pharmaceuticals

Li, Y., Ren, X., Zhang, L., Wang, Y., & Chen, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.901117 · Cited by 76 · see citing works

circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer

Yang, Y., Luo, D., Shao, Y. W., Shan, Z., Liu, Q., Weng, J., He, W., Zhang, R., Li, Q., Wang, Z., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12380 · Cited by 77 · see citing works

Tofacitinib Promotes Functional Recovery after Spinal Cord Injury by Regulating Microglial Polarization via JAK/STAT Signaling Pathway

Ma, H., Wang, C., Han, L., Kong, F., Liu, Z., Zhang, B., Chu, W., Wang, H., Wang, L., Li, Q., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.84564 · Cited by 77 · see citing works

Natural withanolides, an update

Xia, G., Cao, S., Chen, L., & Qiu, F. (2021) · Natural Product Reports · doi:10.1039/d1np00055a · Cited by 73 · see citing works

DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target

Cao, J., Chen, X., Chen, L., Lu, Y., Wu, Y., Deng, A., Pan, F., Huang, H., Liu, Y., Li, Y.-C., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103788 · Cited by 75 · see citing works

Role of the JAK-STAT Pathway in Bovine Mastitis and Milk Production

Khan, M. Z., Khan, A. A., Xiao, J., Ma, Y., Ma, J., Gao, J., & Cao, Z. (2020) · Animals · doi:10.3390/ani10112107 · Cited by 71 · see citing works

UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer

Xiao, J., Sun, F., Wang, Y., Лю, Б., Zhou, P., Wang, F., Zhou, H., Ge, Y., Yue, T., Luo, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci158352 · Cited by 69 · see citing works

Molecular Aspects of Senescence and Organismal Ageing—DNA Damage Response, Telomeres, Inflammation and Chromatin

Sławińska, N., & Krupa, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020590 · Cited by 68 · see citing works

Regulation of the JAK/STAT signaling pathway: The promising targets for cardiovascular disease.

Pang, Q.-Y., You, L., Meng, X., Li, Y., Deng, T., Li, D., & Zhu, B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115587 · Cited by 72 · see citing works

Intervention and potential mechanism of non-starch polysaccharides from natural resources on ulcerative colitis: A review

Wang, Y., Li, Q.-M., Zha, X., & Luo, J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.04.208 · Cited by 67 · see citing works

JAK/STAT in leukemia: a clinical update

Liang, D., Wang, Q.-L., Zhang, W., Tang, H., Song, C., Yan, Z., Liang, Y., & Wang, H. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01929-1 · Cited by 67 · see citing works

Anti-Inflammatory Activity of Thymol and Thymol-Rich Essential Oils: Mechanisms, Applications, and Recent Findings

Gago, C., Serralheiro, A., & Miguel, M. G. (2025) · Molecules · doi:10.3390/molecules30112450 · Cited by 72 · see citing works

Neuropathophysiology of coronavirus disease 2019: neuroinflammation and blood brain barrier disruption are critical pathophysiological processes that contribute to the clinical symptoms of SARS-CoV-2 infection

Welcome, M. O., & Mastorakis, N. E. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00806-x · Cited by 65 · see citing works

A detailed overview of quercetin: implications for cell death and liver fibrosis mechanisms

Xiong, F., Zhang, Y., Li, T., Tang, Y., Song, S., Zhou, Q., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1389179 · Cited by 64 · see citing works

Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors

Dinakar, Y. H., Kumar, H., Mudavath, S. L., Jain, R., AJMEER, R., & Jain, V. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120996 · Cited by 63 · see citing works

Molecular mechanisms and signaling pathways of black cumin (Nigella sativa) and its active constituent, thymoquinone: a review

Sadeghi, E., Imenshahidi, M., & Hosseinzadeh, H. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08363-y · Cited by 63 · see citing works

Molecular Targets of Brown Algae Phlorotannins for the Therapy of Inflammatory Processes of Various Origins

Besednova, N. N., Andryukov, B. G., Zaporozhets, T. S., Kuznetsova, T. A., Kryzhanovsky, S. P., Ermakova, S. P., Galkina, I. V., & Shchelkanov, M. Y. (2022) · Marine Drugs · doi:10.3390/md20040243 · Cited by 65 · see citing works

Targeting breast cancer stem cells through retinoids: A new hope for treatment

Jan, N., Sofi, S., Qayoom, H., Haq, B. U., Shabir, A., & Mir, M. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104156 · Cited by 62 · see citing works

The pivotal role of JAK/STAT and IRS/PI3K signaling pathways in neurodegenerative diseases: Mechanistic approaches to polyphenols and alkaloids

Kooshki, L., Zarneshan, S. N., Fakhri, S., Moradi, S. Z., & Echeverría, J. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154686 · Cited by 61 · see citing works

JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases

Chikhoune, L., Poggi, C., Moreau, J., Dubucquoi, S., HACHULLA, E., Collet, A., & Launay, D. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.10.452 · Cited by 61 · see citing works

Neuroinflammation in retinitis pigmentosa: Therapies targeting the innate immune system

Zhao, L., Hou, C., & Yan, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059947 · Cited by 61 · see citing works

Oxidative stress as a culprit in diabetic kidney disease

Su, S., Ma, Z., Wu, H., Xu, Z., & Yi, H. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121661 · Cited by 60 · see citing works

miRNAs as potential game-changers in bone diseases: Future medicinal and clinical uses

Doghish, A. S., Elballal, M. S., Elazazy, O. E., Elesawy, A. E., Shahin, R. K., Midan, H. M., Sallam, A.-A. M., Elbadry, A. M. M., Mohamed, A. K. I., Ishak, N. W., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154440 · Cited by 60 · see citing works

Immunometabolism in the pathogenesis of asthma

Qin, Z., Chen, Y., Wang, Y., Xu, Y., Liu, T., Mu, Q., & Huang, C. (2023) · Immunology · doi:10.1111/imm.13688 · Cited by 63 · see citing works

Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications

Park, H., Lee, S.-H., Lee, J., Moon, H., & Ro, S. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813764 · Cited by 59 · see citing works

JAK/STAT3 signaling in cardiac fibrosis: a promising therapeutic target

Jiang, H., Yang, J., Li, T., Wang, X., Fan, Z., Ye, Q., & Du, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1336102 · Cited by 61 · see citing works

Regulators involved in trophoblast syncytialization in the placenta of intrauterine growth restriction

Zhou, H., Zhao, C., Wang, P., Yang, W., Zhu, H., & Zhang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1107182 · Cited by 59 · see citing works

Anti-inflammatory effects of Allium cepa L. peel extracts via inhibition of JAK-STAT pathway in LPS-stimulated RAW264.7 cells

Lee, H., Kwon, Y., Seo, E., Kim, S., Lee, H., Lee, J.-T., Chang, P., Choi, Y. J., Lee, S. H., & Ye, S. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116851 · Cited by 58 · see citing works

Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment

Tang, H., Yonghong, P., Yu-feng, Z., & Haitao, T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.018 · Cited by 57 · see citing works

Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review

Liu, Y., Huang, J., Li, S., Li, Z., Chen, C., Qu, G., Chen, K., Teng, Y., Ma, R., Wu, X., et al. (2023) · Biomaterials Science · doi:10.1039/d3bm01645e · Cited by 59 · see citing works

Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations

Akter, K., Gul, K., & Mumtaz, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090716 · Cited by 56 · see citing works

Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance

Wang, X., Lee, J., & Xie, C. (2022) · Cancers · doi:10.3390/cancers14020381 · Cited by 53 · see citing works

The role of peroxisome proliferator‐activated receptor γ in lipid metabolism and inflammation in atherosclerosis

Yang, X.-F., & Shang, D. (2023) · Cell Biology International · doi:10.1002/cbin.12065 · Cited by 53 · see citing works

A literature review: mechanisms of antitumor pharmacological action of leonurine alkaloid

Cao, Q., Wang, Q., Wu, X., Zhang, Q., Huang, J., Chen, Y., You, Y., Qiang, Y., Huang, X., Qin, R., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1272546 · Cited by 53 · see citing works

Traditional Chinese medicine in regulating macrophage polarization in immune response of inflammatory diseases

Chen, S., Zeng, J., Li, R., Zhang, Y., Tao, Y., Hou, Y., Yang, L., Zhang, Y., Wu, J., & Meng, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117838 · Cited by 54 · see citing works

Research progress of targeted therapy regulating Th17/Treg balance in bone immune diseases

Wang, X.-X., Sun, B., Wang, Y., Gao, P., Song, J., Chang, W., Xiao, Z., Xi, Y., Li, Z., An, F.-Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1333993 · Cited by 59 · see citing works

Janus kinase inhibitors for the treatment of COVID-19

Kramer, A., Prinz, C., Fichtner, F., Fischer, A.-L., Thieme, V., Grundeis, F., Spagl, M., Seeber, C., Piechotta, V., Metzendorf, M., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015209 · Cited by 51 · see citing works

Thyroid hormones act as modulators of inflammation through their nuclear receptors

Lasa, M., & Contreras‐Jurado, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.937099 · Cited by 56 · see citing works

Brain–immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders

Zhao, F., Li, B., Yang, W., Ge, T., & Cui, R. (2022) · Cell Proliferation · doi:10.1111/cpr.13295 · Cited by 47 · see citing works

Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms

Chen, J., Shen, B., & Jiang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.978558 · Cited by 52 · see citing works

Genetic polymorphisms in immune- and inflammation-associated genes and their association with bovine mastitis resistance/susceptibility

Khan, M. Z., Wang, J., Ma, Y., Chen, T., Ma, M., Ullah, Q., Khan, I. M., Khan, A. A., Cao, Z., & Liu, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1082144 · Cited by 53 · see citing works

JAK-STAT Signaling in Autoimmunity and Cancer

Parveen, S., Fatma, M., Mir, S. S., Dermime, S., & Shahab Uddin, M. S. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485670 · Cited by 51 · see citing works

CRLF1 and CLCF1 in Development, Health and Disease

Crisponi, L., Buers, I., & Rutsch, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020992 · Cited by 47 · see citing works

Deucravacitinib in the treatment of psoriasis

Estevinho, T., Lé, A. M., & Torres, T. R. (2022) · Journal of Dermatological Treatment · doi:10.1080/09546634.2022.2154122 · Cited by 46 · see citing works

Mechanical sensing protein PIEZO1 controls osteoarthritis via glycolysis mediated mesenchymal stem cells-Th17 cells crosstalk

Zhou, Y., Li, M., Lin, S., Zhu, Z., Zhuang, Z., Cui, S., Chen, L., Zhang, R., Wang, X., Shen, B., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07577-1 · Cited by 46 · see citing works

Sympathetic Blockade of the Acutely Injured Heart

Jayaram, B., & Arbulu, A. (1968) · Diseases of the Chest · doi:10.1378/chest.53.4.487 · Cited by 1 · see citing works

The JAK/STAT signaling pathway: from bench to clinic

Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633 · see citing works

The Structure-Function Bonhomie of JAK-STAT Molecules

Goswami, R. (2020) · CRC Press eBooks · doi:10.1201/9781351042468-2 · Cited by 1 · see citing works

JAK/STAT Signaling: From Mechanisms to Emerging Therapeutics

Singh, S., Kumari, A., Humtsoe, C. T., & Rajan, R. K. (2026) · Current Signal Transduction Therapy · doi:10.2174/0115743624431681260219062438

Janus Kinases and Autoimmunity: Bridging Pathways to Therapy

Wei, Y., & Zhang, T. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100007 · Cited by 1 · see citing works